上海交大赵大海做客央视演播室：奥密克戎新变体给全球新冠疫情防控带来更大挑战
上海交通大学国际与公共事务学院教授、博士生导师，上海交通大学-耶鲁大学卫生政策联合研究中心执行主任赵大海，自新冠肺炎疫情暴发以来，对于新冠疫情暴发、防控以及卫生政策第66次接受央视专访，也是第112次接受央视、上视专访。2021年11月28日，赵大海做客中央电视台英语频道演播室（上海），在《今日世界》节目，就新冠病毒的奥密克戎新变体及其相应的防控策略等话题接受了央视英语频道记者陈童的专访。现将访谈内容翻译并摘录如下。
主持人：世界卫生组织刚刚将在南非检测到的新冠状病毒变异毒株命名为奥密克戎(Omicron)。根据我们目前对该变异毒株的了解，这种Omicron变体会有多么强大？
赵大海：考虑到奥密克戎是一种全新的新冠变体，我们还不知道该变异体的具体细节，但目前的证据已表明，该变体的传播速度比以前的变体要快得多。此外，由于该变异体比之前的新冠病毒变异体具有更多的基因突变，奥密克戎必然比之前的新冠病毒及其变异体更加危险。因而，强大的奥密克戎新冠病毒变异体，值得各国政府和公众的高度关注。
主持人：目前，我们确实有一些药物来对付新冠病毒，但随着在南非发现的该新变种，你认为这意味着我们必须要重新开始进行药物试验吗？
赵大海：如果能预防或治疗新冠病毒及其之前变异体的药物，依然对奥密克戎变异体有效，那就不需要重新开始试验新的药物；目前我们必须要等待现有药物对于奥密克戎变异体有效性的实验室检测和临床试验的检验结果。
主持人：中国现在正在承受来自新冠病毒德尔塔变异体的防控压力，奥密克戎新变异体会给中国带来更大的压力吗？
赵大海：奥密克戎新变体的出现，充分证明中国所坚持的新冠病毒“动态清零”策略的科学性和正确性。奥密克戎变异体的出现不会对中国的新冠疫情防控战略产生重大影响，我们将继续保持动态清零的策略。与此同时，鉴于奥密克戎新变异体的高传染性和高变异性，必然对中国的新冠疫情防控带来更大的挑战。
供稿者：国务学院
日期：2021年11月30日
Dahai ZHAO Joined CGTN Shanghai Studio: Omicron variant poses fresh challenge to global COVID containment
Dahai Zhao, a doctoral supervisor at SJTU School of International and Public Affairs, the Executive Director of YALE-SJTU Joint Research Center for Health Policy, has been interviewed by CGYN for the 66th time (112 times by CGTN / ShanghaiTV altogether) since the COVID-19 pandemic. On 28 November, Zhao joined CGTN Shanghai studio. When interviewed by CHEN Tong, a journalist of CGTN Shanghai, ZHAO commented on the Omicron variant and its corresponding prevention and control strategies on “The World Today”.
CHEN：WHO has has just named the new Coronavirus detected in South Africa Omicron, so based on our current knowledge about it, how powerful is this so-called Omicron variant?
ZHAO：Considering Omicron variant is a brand new variant, we have not known the details of this variant, however the current evidence has shown that this variant has much faster spread speed than the previous variant. This variant is much more dangerous because this variant has much more mutations than the prior viruses, therefore, this variant which is powerful needs to be paid for attention by the government and the public in all countries.
CHEN：At current moment, we do have some drugs to tackle the Coronavirus, but with the new variant being detected in South Africa, do you think that will mean we have to start over again?
ZHAO：If the drug which is effective in treating the original Cronavirus and other Cronavirus variant, if this treatment works with the Omicron variant, of course it is not necessary for us to start all over again, so we have to wait for the outcome of the clinical and lab tests on this effectiveness against the Omicron variant.
CHEN：China is now taking pressure from the Delta variant with the new Omicron variant, do you think that will put more pressure on China?
ZHAO：First of all, the appearance of the Omicron variant and has fully shown that the China's combating Covid-19 strategy that is the zero clearing strategy is scientific and right. The appearance of Omicron variant will not influence dramatically China's strategy, we will continue to keep the zero clearance strategy.
Contributor: SIPA, SJTU
Date: November 30, 2021